365,074 Royalty Pharma PLC $RPRX Shares Sold by Aberdeen Group plc

Royalty Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Aberdeen Group cut its Royalty Pharma stake by 63.1% in the third quarter, selling 365,074 shares and retaining 213,127 shares valued at about $12.4 million.
  • Royalty Pharma declared a quarterly dividend of $0.235 per share, equal to $0.94 annually and a 1.4% yield.
  • Analyst sentiment was broadly positive: the stock had an overall “Buy” rating, with recent price-target increases from Citigroup and TD Cowen, though its average target was $65.
  • Five stocks to consider instead of Royalty Pharma.

Aberdeen Group plc trimmed its position in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 63.1% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 213,127 shares of the biopharmaceutical company's stock after selling 365,074 shares during the quarter. Aberdeen Group plc's holdings in Royalty Pharma were worth $12,438,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of RPRX. Renaissance Technologies LLC bought a new stake in shares of Royalty Pharma during the first quarter worth $37,941,000. Bank of America Corp DE boosted its stake in shares of Royalty Pharma by 29.0% during the first quarter. Bank of America Corp DE now owns 3,495,846 shares of the biopharmaceutical company's stock valued at $167,696,000 after purchasing an additional 786,921 shares during the period. Carmignac Gestion purchased a new stake in shares of Royalty Pharma during the first quarter valued at $30,279,000. Congress Asset Management Co. bought a new position in shares of Royalty Pharma in the third quarter worth about $30,761,000. Finally, Amundi grew its holdings in shares of Royalty Pharma by 15.3% in the first quarter. Amundi now owns 3,088,773 shares of the biopharmaceutical company's stock worth $148,168,000 after purchasing an additional 409,394 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Stock Down 0.0%

Shares of NASDAQ RPRX opened at $68.67 on Thursday. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.77. The stock has a market capitalization of $39.39 billion, a PE ratio of 57.23, a price-to-earnings-growth ratio of 1.36 and a beta of 0.37. The stock's fifty day simple moving average is $61.93 and its two-hundred day simple moving average is $54.95. Royalty Pharma PLC has a 12-month low of $37.31 and a 12-month high of $70.37.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $0.2350 dividend. The ex-dividend date is Friday, November 13th. This represents a $0.94 dividend on an annualized basis and a yield of 1.4%. Royalty Pharma's payout ratio is currently 78.33%.

Insider Buying and Selling at Royalty Pharma

In other news, EVP Marshall Urist sold 4,126 shares of the firm's stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $57.10, for a total value of $235,594.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of the firm's stock in a transaction dated Tuesday, November 17th. The shares were sold at an average price of $68.15, for a total transaction of $6,815,000.00. Following the completion of the sale, the executive vice president owned 177,523 shares in the company, valued at $12,098,192.45. This represents a 36.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 440,788 shares of company stock valued at $29,157,162. 18.84% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RPRX. Citigroup upped their target price on shares of Royalty Pharma from $70.00 to $78.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. Zacks Research raised shares of Royalty Pharma from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, November 11th. Wall Street Zen upgraded Royalty Pharma from a "buy" rating to a "strong-buy" rating in a report on Saturday, November 14th. Weiss Ratings upgraded Royalty Pharma from a "buy (b-)" rating to a "buy (b)" rating in a report on Monday, September 14th. Finally, TD Cowen increased their price objective on Royalty Pharma from $68.00 to $80.00 and gave the stock a "buy" rating in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the stock. Based on data from MarketBeat.com, Royalty Pharma currently has an average rating of "Buy" and an average target price of $65.00.

Read Our Latest Research Report on Royalty Pharma

Royalty Pharma Company Profile

(Free Report)

Royalty Pharma plc is a biopharmaceutical royalty company that provides funding to companies and inventors in exchange for royalty interests in medicines. It acquires existing royalties and helps finance drug development and commercialization through royalty-based transactions and other forms of funding. The company's portfolio includes royalty interests in medicines across a range of therapeutic areas, spanning both approved treatments and products in development. Royalty Pharma generally earns revenue when these medicines are sold; it does not operate as a conventional drug manufacturer or commercialize medicines itself.

Featured Stories

Institutional Ownership by Quarter for Royalty Pharma (NASDAQ:RPRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Royalty Pharma Right Now?

Before you consider Royalty Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Royalty Pharma wasn't on the list.

While Royalty Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines